» Articles » PMID: 12150994

E2F4/5 and P107 As Smad Cofactors Linking the TGFbeta Receptor to C-myc Repression

Overview
Journal Cell
Publisher Cell Press
Specialty Cell Biology
Date 2002 Aug 2
PMID 12150994
Citations 215
Authors
Affiliations
Soon will be listed here.
Abstract

Smad3 is a direct mediator of transcriptional activation by the TGFbeta receptor. Its target genes in epithelial cells include cyclin-dependent kinase inhibitors that generate a cytostatic reponse. We defined how, in the same context, Smad3 can also mediate transcriptional repression of the growth-promoting gene c-myc. A complex containing Smad3, the transcription factors E2F4/5 and DP1, and the corepressor p107 preexists in the cytoplasm. In response to TGFbeta, this complex moves into the nucleus and associates with Smad4, recognizing a composite Smad-E2F site on c-myc for repression. Previously known as the ultimate recipients of cdk regulatory signals, E2F4/5 and p107 act here as transducers of TGFbeta receptor signals upstream of cdk. Smad proteins therefore mediate transcriptional activation or repression depending on their associated partners.

Citing Articles

p53 regulates DREAM complex-mediated repression in a p21-independent manner.

Agrawal R, Sengupta S EMBO J. 2025; .

PMID: 40038454 DOI: 10.1038/s44318-025-00402-7.


Non-small cell lung cancer map and analysis: exploring interconnected oncogenic signal integrators.

Gottumukkala S, Palanisamy A Mamm Genome. 2025; .

PMID: 39939487 DOI: 10.1007/s00335-025-10110-6.


Inflammation and Related Signaling Pathways in Acute Myeloid Leukemia.

Naji N, Sathish M, Karantanos T Cancers (Basel). 2024; 16(23).

PMID: 39682161 PMC: 11640130. DOI: 10.3390/cancers16233974.


Advancements in TGF-β Targeting Therapies for Head and Neck Squamous Cell Carcinoma.

Britton W, Cioffi I, Stonebraker C, Spence M, Okolo O, Martin C Cancers (Basel). 2024; 16(17).

PMID: 39272905 PMC: 11394608. DOI: 10.3390/cancers16173047.


The paradoxical role of transforming growth factor-β in controlling oral squamous cell carcinoma development.

Peng R, Huang Y, Huang P, Liu L, Cheng L, Peng X Cancer Biomark. 2024; 40(3-4):241-250.

PMID: 39213051 PMC: 11380267. DOI: 10.3233/CBM-230354.